The Epworth Sleepiness Scale: Self‐Administration Versus Administration by the Physician, and Validation of a French Version

Kamińska, Marta; Jobin, Vincent; Mayer, Pierre; Amyot, R; Perraton-Brillon, Mélanie; Bellemare, F.

doi:10.1155/2010/438676

Cited by 84 publications

(48 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reported by Kaminska and others, 26 the selfadministered ESS scores were higher than the scores given by the physician. Since this study was interviewer administered the ESS scores resulted might be lower than the self-rated ESS scores of this study sample.…”

Section: Discussionsupporting

confidence: 49%

Level of fatigue and daytime sleepiness among heavy vehicle drivers in Sri Lanka

Gunawardane

Dharmaratne

2015

SE Asia J. Pub. Health

View full text Add to dashboard Cite

Heavy vehicle crash rates are high in Sri Lanka. International studies showed that fatigue and day time sleepiness are linked to heavy vehicle crashes. The aim of this study is to examine the level of fatigue, day time sleepiness and their associated factors among heavy vehicle drivers in Sri Lanka. A descriptive cross-sectional study was carried out in 403 heavy vehicle drivers through an interviewer administered structured questionnaire consisting of the 'Fatigue Severity Scale' (FFS) and the 'Epworth Sleepiness Scale' (ESS). The mean age of the study sample was 36.5+8.6 years and all were males. They drive an average of 129.03+87.24 km/day. It was found that the mean FFS score in the study participants was 2.43+0.99 and the mean ESS score was 6.57+4.07. Prevalence of fatigue (FSS score >4) was 8.7% (n=35) and the prevalence of excessive day time sleepiness (EDS) (ESS score >10) was 14.4% (n=58). Working for non-fixed schedule, married marital status, and working more than 11 hours/day are found to be significant risk factors for being fatigue. Drivers who were having night sleep of less than 6 hours were found to have a higher risk of EDS. A high prevalence of fatigue (8.7%) and EDS (14.4%) among heavy vehicle drivers was found which may link to heavy vehicle crashes. The occupational health service providers should be aware of the possibility of fatigue and daytime sleepiness in heavy vehicle drivers and its overall risk on the roads to take necessary actions.

show abstract

Section: Discussionsupporting

confidence: 49%

Level of fatigue and daytime sleepiness among heavy vehicle drivers in Sri Lanka

Gunawardane

Dharmaratne

2015

SE Asia J. Pub. Health

View full text Add to dashboard Cite

show abstract

“…Studies published so far are inconsistent in this matter. It was demonstrated that the results of the ESS questionnaires carried out by physicians differed from those filled unaided (8.3±5.8 vs. 9.4±5.8, p < 0.0001) [15]. On the other hand, Damiani et al showed that the results of the physician-administered ESS were higher than a conventional, self-administered questionnaire (12.09±4.1 vs. 10.37±5.49, p = 0.01) and were stronger correlated apnea-hypopnea index assessed with portable device [16].…”

Section: Discussionmentioning

confidence: 91%

Reliability of the Epworth Sleepiness Scale and the Berlin Questionnaire for screening obstructive sleep apnea syndrome in the context of the examination of candidates for drivers

Kiciński

Przybylska-Kuć

Tatara³

et al. 2016

Med Pr

View full text Add to dashboard Cite

Background: The aim of the study has been to assess the usefulness of the Epworth Sleepiness Scale (ESS) and the Berlin Questionnaire (BQ) for obstructive sleep apnea syndrome (OSAS) screening. The capacity of both tests to discriminate between healthy individuals or with mild OSAS (apnea-hypopnea index (AHI) < 15/h) vs. patients with moderate or severe OSAS (AHI ≥ 15/h) was evaluated. Material and Methods: The study encompassed 223 patients with a suspicion of the OSAS. The ESS and BQ were completed by patients unassisted. Screening polysomnography was performed using the Porti SleepDoc. The OSAS was diagnosed when AHI ≥ 15/h or AHI ≥ 5/h with simultaneous occurrence of clinical symptoms. Results: The ESS score was found to be significantly higher in the study group compared to the control group (8.9±5.9 vs. 11.6±5.2 pt, p < 0.0001). Otherwise, there were no significant inter-group differences in the percentage of high-risk individuals according to the BQ (83.7% vs. 92.3%, p > 0.05). Sensitivity of the ESS and BQ was 53.2% and 93.1%, respectively while specificity was 58.8% and 16.2%, respectively. Poor correlation between the ESS score and AHI and apnea index were noticed (r = 0.22, p = 0.001 and r = 0.24, p < 0.001, respectively). Conclusions: Considering its low sensitivity, the ESS should not be used as a screening test for the OSAS diagnosis amongst candidates for drivers. The BQ is characterised by high sensitivity for the OSAS diagnosis with AHI ≥ 15/h, however, due to low specificity, the questionnaire may increase the number of healthy individuals referred for needless diagnostic procedures. Med Pr 2016;67(6):721-728

show abstract

“…Medication tolerability and safety in the two treatment groups were evaluated and compared on the basis of change in alertness and mood on final wakening (Recorded as Visual analog scales), Epworth sleepiness scale 22 score to measure day time sleepiness, other adverse events observed during the study, any clinically significant change in the value of laboratory parameters, vital signs and physical examination during the study compared to baseline.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

A Double Blind, Randomized, Parallel Group, Prospective, Clinical Study for Evaluation of Efficacy and Safety of Low Dose Doxepin in Comparision With Zopiclone in Adult and Elderly Patients With Primary Insomnia

Rastogi¹,

Rastogi²

2015

jemds

View full text Add to dashboard Cite

BACKGROUND:Insomnia is underappreciated public health issue. In recent years, insomnia treatment has advanced beyond the routine use of benzodiazepines. AIMS: To compare the efficacy and safety of low dose Doxepin with Zopiclone in patients with primary insomnia. SETTINGS AND DESIGN: A double blind, randomized parallel group, prospective study of low dose Doxepin (n=20) and Zopiclone (n=15) in patients with primary insomnia. METHODS & MATERIAL:Patients fulfilling the selection criteria were enrolled. Enrolled patients were randomized to 2 groups-of low dose Doxepin(3mg) and Zopiclone (3.75mg). Patients were provided with sleep diaries to record sleep parameters, change in alertness and mood, sleepiness scale score and other adverse events were recorded. STATISTICAL ANALYSIS: Student 't' test. RESULTS: Both the groups show significant reduction the time of wakening after sleep onset, with improvement in both total sleep time & sleep efficiency. Both the drugs were well tolerated and percentage change in mood and alertness was comparable. CONCLUSION: Low dose Doxepin was found to be as effective and safe as Zopiclone in patients of primary insomnia. HOW TO CITE THIS ARTICLE:

show abstract

The Epworth Sleepiness Scale: Self‐Administration Versus Administration by the Physician, and Validation of a French Version

Abstract: In a sleep clinic population, the French version of the ESS performed similarly to the English version. However, the systematic underscoring during physician administration may be important to consider in the research setting if questionnaire administration methods are not consistent.

Cited by 84 publications

References 34 publications

Level of fatigue and daytime sleepiness among heavy vehicle drivers in Sri Lanka

Level of fatigue and daytime sleepiness among heavy vehicle drivers in Sri Lanka

Reliability of the Epworth Sleepiness Scale and the Berlin Questionnaire for screening obstructive sleep apnea syndrome in the context of the examination of candidates for drivers

A Double Blind, Randomized, Parallel Group, Prospective, Clinical Study for Evaluation of Efficacy and Safety of Low Dose Doxepin in Comparision With Zopiclone in Adult and Elderly Patients With Primary Insomnia

Contact Info

Product

Resources

About